serum albumin has also been reported for another HER-2 tyrosine kinase inhibitor HKI-272 with a structure closely related to afatinib. The absence of detectable purchase Celecoxib CYP-mediated metabolism suggests that the risk of potential interaction between afatinib and other therapies metabolized by CYP450 enzymes (i.e., CYP substrates, CYP inhibitors and CYP inducers) is minimal. This finding is likely to be a clinical PF-04217903
advantage, since agents interacting via the CYP450 enzyme system are widely used in the treatment for lung cancer patients . In contrast, other tyrosine kinase inhibitors Celecoxib Inflammation (notably erlotinib, gefitinib and lapatinib) are all metabolized by CYP3A4. In conclusion, this study showed that afatinib was mainly eliminated unchanged buy Celecoxib via feces. Overall recovery of radioactivity was 89.5%, indicating a complete mass balance. Renal excretion was low, and no major circulating metabolites were identified. Metabolism therefore plays a negligible role in the overall disposition and elimination of afatinib in humans. Oral
single-dose administration of afatinib was well tolerated. Acknowledgments This study was supported by Boehringer Ingelheim. Editorial assistance was provided with funding from Boehringer Ingelheim. Conflict of interest All authors are employees of Boehringer Ingelheim.